Gastric Cancer
Conditions
Keywords
Elderly Gastric Cancer, Capecitabine Maintenance
Brief summary
To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of elderly advanced gastric cancer (AGC) by comparing it with that of XELOX regimen.
Detailed description
To investigate whether XELOX with capecitabine maintenance treatment as 1st line treatment in the elderly advanced gastric cancer is as effective and safe as XELOX regimen.
Interventions
DRUGOxaliplatin
Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks
DRUGCapecitabine
capecitabine 850mg/m2 bid, d1-14, every 3 weeks
Sponsors
Harbin Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ages Eligible for Study: 65 Years or older * Genders Eligible for Study: Both * The Eastern Cooperative Oncology Group (ECOG) status ≤ 2 * Histologically confirmed gastric adenocarcinoma(including LAUREN type). * Measurable disease(according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1). * chemotherapy naive after recurrence or metastasis. Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more than 6 months. * Hb \> 90g/L, neutrophil count \> or = 1.5\*10\^9/L, platelet \> or = 100\*10\^9/L, alanine transaminase (ALT) and aspartate aminotransferase (AST) \< or = 2.5 times upper limit of nominal (ULN), alkaline phosphatase (ALP) \< or = 2.5 times ULN, total bilirubin (TBIL) \< 1.5 times ULN, serum albumin level \> or = 30g/L, serum creatinine \< 1 times ULN. * No serious concomitant diseases which could lead to death within 5 years. At least 5 years from the last Biological/Immunotherapy/Hormone treatment for Malignancy excluding gastric cancer. * Able to accept oral medication * Compliance with protocol
Exclusion criteria
* Had received cytotoxic chemotherapy, radiotherapy or immunotherapy for this gastric cancer, excluding Corticosteroids. * Other previous malignancy within 5 year, except curative skin cancer or carcinoma in situ of uterine cervix. * Uncontrolled epilepsy, central nervous system disorders, or a history of mental disorders. * clinically significant(i.e. active)cardiac disease e.g. symptomatic coronary artery disease, New York Heart Association (NYHA) II or more serious congestive heart failure or severe requiring medication intervention arrhythmia, or history of myocardial infarction within the last 12 months. * Upper gastrointestinal obstruction or physiological dysfunction or suffering from malabsorption syndrome, which could affect the absorption of capecitabine. * Organ transplantation requires immunosuppressive treatment. * Severe uncontrolled recurrent infections, or Other serious uncontrolled concomitant diseases. * Moderate or severe renal impairment(creatinine clearance (CCr) = or \< 50 ml/min), or serum creatinine \> ULN. * Known enzyme deficiency of dihydropyrimidine dehydrogenase(DPD). * Allergy to Oxaliplatin or any study medication ingredients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival (PFS) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months |
Secondary
| Measure | Time frame |
|---|---|
| overall survival (OS) | from the date of randomization until death from any cause or up to 1 year |
| Response Rate (RR) | evaluate every 6 weeks after the date of randomization until diease progress or up to 12 weeks |
| adverse events (AE) | from date of randomization to 28 days after the last chemo dosage |
Other
| Measure | Time frame | Description |
|---|---|---|
| excision repair cross-complementing 1(ERCC1) expression | assays messager ribonucleic acid (mRNA) of ERCC1 expression in tumor tissue after randomization and before the first treatment | quantitative real-time reverse transcriptase polymerase chain reaction (PCR) assays were performed to determine ERCC1 mRNA expression in tumor tissue. |
| K-ras gene type | assess after randomization and before the first treatment | Genomic Deoxyribonucleic acid (DNA) is extracted from tumor tissue, direct sequencing technique is used to test K-ras gene type(mutation or wild). |
| health-related quality of life (HRQOL) | evaluate every 6 weeks from the date of randomization until 28 days after the last chemo dosage | — |
Countries
China
Contacts
Primary ContactYuxian BAI, PhD
Backup ContactHong SUI, PhD
Outcome results
None listed